Triple therapy of Kaposi’s sarcoma using oral propranolol,oral zinc sulfate and oral acyclovir as new initiative study


  • Khalifa E. Sharquie Department of Dermatology, College of Medicine, University of Baghdad. Medical City Teaching Hospital,Baghdad ,Iraq
  • Raed I. Jabbar Department of Dermatology ,Fallujah Teaching Hospital ,Al-Anbar Health Directorate , Anbar , Iraq.


Kaposi’s Sarcoma, triple therapy, zinc sulfate, acyclovir


Background  Kaposi’s sarcoma (KS) in Iraq had been reported as sporadic cases in elderly of Iraqi population but after the Gulf War 1991, there was marked increase in cases of classic KS among Iraqi people, in concordance with the rise of incidence of other hematological and skin malignancies.   Objective To introduce triple therapy for Kaposi’s sarcoma using oral propranolol, oral zinc sulfate and oral acyclovir as new innovative therapy.   Methods This is case series and therapeutic trial in which seven cases with histopathological proved Kaposi’s sarcoma were included over a twelve months period from 2021 to 2022. All patients were treated by oral propranolol tablet 20mg three times a day, with oral zinc sulfate 100 mg three times a day and acyclovir tablet 800mg three times a day. The duration of therapy continued for three months apart from one case in which the treatment continued for one year. Patients were watched carefully for response to therapy and any adverse reactions were recorded.   Results A total of 7 cases of Kaposi’s sarcoma enrolled in this study during one-year period (2020-2021). The age of the patients ranged from 50-60 years with 6 (85.71%) males and one (14.28%) female. The duration of the skin lesions ranged from 2 to 13 months with a mean±SD of 7.85±3.97 months. The lower limbs were the most commonly involved site in 4 (57.14%) cases. In all patients the improvement to therapy was started two weeks after starting the treatment. After 3 weeks, all patients showed obvious decrease in the size of the skin lesions with marked reduction in the size of the lesions achieved after 1.5 months. Ultimately, the lesions and associated signs and symptoms were completely vanished after three months leaving only hyperpigmented macules or patches.   Conclusion This is new effective innovative triple therapy for Kaposi sarcoma using oral propranolol, oral zinc sulfate and oral acyclovir. This new regimen of treatment has both therapeutic and prophylactic effects. Further studies are highly recommended using large series of patients and longer duration of therapy to have more confirmed therapeutic response.  


Curtiss P, Strazzulla LC, Friedman-Kien AE. An Update on Kaposi's sarcoma: Epidemiology, Pathogenesis and Treatment. Dermatol Ther (Heidelb). 2016;6(4):465-70.

North PE, Kincannon J. Vascular neoplasms and neoplastic-like proliferations. In: Bolognia J L, Jorizzo JL , Schaffer JV, Eds., Dermatology, 3rd Edition, Elsevier Saunders, 2012;114:1932-1935.

Mandong BM, Chirdan LB, Anyebe AO, Mannaseh AN. Histopathological study of Kaposi’s sarcoma in Jos: a 16 year review. Ann Afr Med. 2004;3:174-6.

Slavin G, Cameron HM. Kaposi’s sarcoma in East African children. J Pathol. 1970; 100:187-99.

Kyalwazi SIC. Histological classification of Kaposi’s sarcoma: a basis for chemotherapy. East Afr Med J. 1976;53:670-6.

Stein ME, Spencer D, Ruff P, et al. Endemic African Kaposi sarcoma: clinical and therapeutic implications, 10-year experience in Johannesburg Hospital (1980–1990). Oncology. 1994;51:63-9.

Al-Saleem T, Sharquie K, Alash N, et al. Kaposi’s sarcoma in Iraqi patients. Proceedings of the first scientific conference of Medical College, University of Baghdad; 1984 April 24; Baghdad, Iraq.

Al-Waiz M, Sharquie K E, Al-Hamdani GA. Un upsurge of new cases of Kaposi’s sarcoma in Iraqi patients. Saudi Med J.2003;24:224-5.

Appero J W, Conant M A, Wolfe SF, Berger T G. Kaposis Sarcoma. epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. JAAD. 1993; 28:371-95.

Storch C H , Hoeger P H. Propranolol for infantile heamangiomas: Insight into the molecular mechanism of action. BJD.2010; 163:269-74.

Sharquie K.E. Jabbar. R I. Triple therapy for acute and chronic cutaneous leishmaniasis using oral zinc sulfate, oral ketoconazole and topical podophyllin. J Pak Assoc Dermatol. 2022;32(3):502-9.

Sharquie K E. Jabbar R I. Medical therapy of burn scar before any plastic surgery by using topical corticosteroid combined with oral zinc sulfate. J Turk Acad Dermatol. 2021;15(2):37-43.

Sharquie K E , Khorsheed, A A , Al-Nuaimy A A. (2007) Topical zinc sulphate solution for treatment of viral warts. Saudi Med J. 2007;28:1418-21.

Sharquie K E, Noaimi A A. Treatment of Kaposi’s Sarcoma by combination of zinc sulfate and propranolol. J Cosmet Dermatol Sci App.2018;8:249-55.

Kłysik K, Pietraszek A, Karewicz A, Nowakowska M. Acyclovir in the treatment of herpes viruses - A Review. Curr Med Chem. 2020;27(24):4118-37.

Al-Waiz M, Sharquie KE, Al-Hamdani GA. An upsurge of new cases of Kaposi's sarcoma in Iraqi patients. Saudi Med J. 2003;24(2):224-5.

Sharquie KE, Noaimi A A, Taha S F. Kaposi sarcoma is increasing over years. Am J Dermatol Venereol.2019;8(5):84-7.

Al-Hamamy H, Sharquie KE, Naomi A, Abdulwahhab W. Mycosis Fungoides in Iraqi patients-clinical, histopathological and immunohistochemical study. J Cosmet Dermatol Sci Appl. 2015;5(2):116-24.

Sharquie KE, Al-Jaralla FA, Al-Saadawi AR. Hyperpigmented lichenoid mycosis fungoides as a new variant: clinical and histopathological evaluation. Our Dermatol Online. 2020;11(e):e168.1-e168.5

Sharquie KE, Al-Jaralla FA, Taha S F. Mycosis fungoides in Iraqi population; changing in frequency, demographic and clinical subtypes. J Pak Assoc Dermatol. 2022;32(3):510-16.

Bertell R. Depleted uranium: All the questions about DU and Gulf War syndrome are not yet answered. Int J Health Serv. 2006;36:17.

Hagopian A, Lafta R,Hassan J, et al. Trends in childhood leukemia in Basrah, Iraq, 1993- 2007. Am J Public Health. 2010;100:1081-7.

Chalya, P.L., Mbunda, F., Rambau, P.F. et al. Kaposi’s sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania. BMC Res Notes.2015; 8:440.

Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. 2015. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med.2015;372:735-46.

Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics.2013;131:128-40.

Moses AV, Fish KN, Ruhl R, et al. Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol. 1999;73:6892-902.

Casper C. Defining a role for antiviral drugs in the treatment of persons with HHV-8 infection. Herpes. 2006;13:42-7.

Mohammed Z B, Abdullah S F. Serodiagnosis of Human Herpesvirus – 8 among Iraqi Blood Donors. Eur J Mol Clin Med.2020;7(2):69-74.




How to Cite

Sharquie KE, Jabbar RI. Triple therapy of Kaposi’s sarcoma using oral propranolol,oral zinc sulfate and oral acyclovir as new initiative study . J Pak Assoc Dermatol [Internet]. 2023Mar.5 [cited 2024May22];33(1):72-7. Available from:



Original Articles

Most read articles by the same author(s)